Microalbuminuria and cardiovascular risk

Area of Science:

• Nephrology
• Cardiology
• Vascular Biology

Background:

• Microalbuminuria indicates widespread vascular dysfunction, affecting 6-10% of general populations in the US and Europe.
• Elevated albumin excretion rates, even within normal limits, are linked to increased cardiovascular morbidity and mortality.
• Microalbuminuria independently predicts renal disease, stroke, myocardial infarction, and left ventricular dysfunction.

Purpose of the Study:

• To highlight microalbuminuria as a critical marker for cardiovascular risk.
• To emphasize the prognostic value of screening for microalbuminuria.
• To review therapeutic strategies for managing microalbuminuria and its associated risks.

Main Methods:

• Analysis of prevalence data from population surveys.
• Review of clinical studies demonstrating the independent risk associated with microalbuminuria.
• Evaluation of evidence supporting antihypertensive therapies, particularly renin-angiotensin system blockade.

Main Results:

• Microalbuminuria doubles cardiovascular event risk in type 2 diabetes patients, independent of traditional risk factors.
• Urinary albumin excretion predicts target organ damage, including renal disease and cardiovascular events.
• Antihypertensive therapy, especially renin-angiotensin system inhibitors, effectively controls and can reverse microalbuminuria.

Conclusions:

• Screening for microalbuminuria provides crucial prognostic information for cardiovascular risk assessment.
• Blockade of the renin-angiotensin system is the preferred treatment for microalbuminuria, halting or reversing progression.
• Therapeutic interventions can prevent the progression of renal disease and improve cardiovascular outcomes.